Evaluation of the Safety, Feasibility, and Early Clinical Outcomes of Patient-Specific Bone Defect Implants Fabricated From Titanium Alloy (Ti-6Al-4V) Using 3D Printing Technology

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorVinUniversity

About this trial

The goal of this clinical trial is to evaluate the safety and feasibility of patient-specific bone defect implants fabricated from Ti-6Al-4V using 3D printing technology and to assess early clinical outcomes within the first 12 months following implantation of these customized devices. The main question it aims to answer is: "In patients with bone defects requiring surgical reconstruction, are patient-specific bone defect implants fabricated from titanium alloy (Ti-6Al-4V) using 3D printing technology - designed and produced at VinUni, safe and feasible for clinical use, and do they result in favorable early clinical outcomes within the first 12 months following implantation?"

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosed with a bone defect requiring surgical reconstruction, as determined by the treating orthopedic surgeon

Suitable candidate for implantation of a patient-specific device manufactured from Ti-6Al-4V

Able to undergo preoperative imaging (CT ± MRI) required for implant design

Willing and able to provide written informed consent

Disqualifiers

Active systemic or local infection at the surgical site at the time of implantation

Known hypersensitivity or allergy to titanium or titanium alloys

Severe uncontrolled comorbidities that significantly increase surgical risk (e.g., uncontrolled diabetes, severe cardiovascular disease)

Pregnant or breastfeeding women

Trial design

Design model

Single group

Treatments tested in this trial

  • Patient-specific 3D-printed Ti-6Al-4V bone implant

    Device

    The investigational device is a patient-specific bone implant manufactured from titanium alloy Ti-6Al-4V using metal additive manufacturing technology. The implant is designed individually for each patient based on medical imaging data (CT or MRI), which are converted from DICOM format into three-dimensional digital models for anatomical reconstruction and implant design. The device is fabricated using selective laser melting (SLM) technology, in which high-power laser beams selectively fuse layers of Ti-6Al-4V powder to produce the final implant geometry. The manufacturing process is performed on a metal additive manufacturing system under an inert gas environment to prevent oxidation and ensure material integrity. Titanium powder feedstock complies with ASTM F2924 specifications for medical-grade Ti-6Al-4V used in powder bed fusion processes. Following printing, implants undergo standardized post-processing procedures including support removal, surface cleaning and finishing, stress-

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: Patient-specific 3D-printed Ti-6Al-4V implant reconstructionExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Number of Participants with Major Postoperative Complications

Assessment of major postoperative complications related to the implant or surgical procedure (Yes/No), based on clinical examination and medical record review.

Time frame
1-4 weeks postoperatively and from 6 weeks up to 12 months postoperatively
2

Number of Participants with Early Local Complications

Assessment of early local complications including wound discharge, bleeding, swelling, pain, and sensory disturbance, evaluated using standardized clinical examination.

Time frame
Within 4 weeks postoperatively
3

Number of Participants with Early Systemic Complications

Assessment of early systemic complications including sepsis, hemodynamic instability, and respiratory failure, based on clinical evaluation and inpatient medical records.

Time frame
Within 4 weeks postoperatively
4

Number of Participants with Late Implant-Related Complications

Assessment of late implant-related complications including implant loosening, sinus tract formation, and persistent pain, evaluated through clinical examination.

Time frame
From 6 weeks up to 12 months postoperatively

Secondary outcomes

1

Number of Participants with Implant Stability (No Implant Loosening)

Assessment of implant stability defined as absence of implant loosening (Yes/No), evaluated by clinical examination and imaging (X-ray or CT).

Time frame
At 3, 6, and 12 months postoperatively
2

Rate of Successful Bone-Implant Integration on Imaging

Assessment of osseointegration based on imaging findings (X-ray or CT), defined as absence of radiolucent lines and presence of a stable bone-implant interface.

Time frame
At 3, 6, and 12 months postoperatively
3

Number of Participants with restoration of Anatomical Structure

Assessment of postoperative anatomical reconstruction (e.g., limb morphology) using clinical evaluation and imaging documentation.

Time frame
Postoperative period and at 12 months postoperatively
4

Change in Pain Score Measured by Visual Analog Scale (VAS)

Pain intensity will be assessed using the Visual Analog Scale (VAS), a standardized 0-10 scale, with higher scores indicating greater pain.

Time frame
Baseline and at 1, 3, 6, and 12 months postoperatively

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

VinUniversity

Lead sponsor

Vinmec Healthcare System

Collaborator

This trial is not recruiting at the moment. You can still explore other options: